Tribendimidine is primarily used as an anthelmintic agent, effective against a range of parasitic worm infections. It is particularly valuable in treating soil-transmitted helminthiases such as hookworm, roundworm, and whipworm infections in humans. Its mechanism of action involves acting on nicotinic acetylcholine receptors in the nervous system of parasites, leading to paralysis and eventual expulsion from the host. The compound shows high efficacy, especially against hookworms, including some strains that exhibit reduced sensitivity to other anthelmintics like albendazole. This makes tribendimidine a potential alternative in resistance management strategies. It has been used in public health programs in endemic regions, particularly in parts of China and other developing countries, as part of mass drug administration campaigns. Tribendimidine is also being studied for use in pediatric populations due to its favorable safety profile and effectiveness at single doses. Ongoing research explores its broader spectrum, including activity against other intestinal parasites and potential application in veterinary medicine.